Mylan Inks $465M Deal Over EpiPen Rebates
Mylan Inc. on Friday said it has reached a $465 million deal with the U.S. Department of Justice to resolve an investigation into its controversial classification of allergy treatment EpiPen as...To view the full article, register now.
Already a subscriber? Click here to view full article